Novel prognostic for LUPUS

VIRGINIA-BASED AMPEL BIOSOLUTIONS’ NOVEL PROGNOSTIC TECHNOLOGY WITH SUGGESTED THERAPIES

LuGENE®️: AMPEL’S NOVEL PROGNOSTIC TECHNOLOGY PREDICTS DISEASE ACTIVITY AND IDENTIFIES TREATMENTS FOR LUPUS PATIENTS

Recent research by AMPEL BioSolutions is primed to improve outcomes for individuals with Lupus.  Published in Nature Scientific Reports this study details AMPEL’s innovative machine learning approach to predict disease activity from gene data obtained from patient blood samples.

AMPEL’s machine learning approach is a significant step towards implementing a routine blood test for monitoring disease activity and providing decision support for drugs prescribed based on a patient’s gene expression profile. This will transform the way doctors treat chronic diseases by using the information gathered by the lab test and analyzed by machine learning to predict a flare and treat it before it even begins, saving patients from pain and inconvenience of a disease that otherwise drastically affects their lives. 

HOW AMPEL'S LuGENE®️ APPROACH WORKS

Prognosis

A patient sample (blood drawn in a lab) is processed to extract RNA from human cells. Bioinformatic tools on AMPEL’s Genomic Platform (AGP®️) analyze patient RNA for gene expression that  predicts disease activity and potentially effective treatments. The results give physicians a greater understanding of an individual’s current inflammatory/autoimmune response to Lupus with a report of suggested treatments already on the market.

Patients of chronic autoimmune diseases, like Lupus, often suffer from unpredictable flares that impact daily activities like work and family life. Since unpredicted flares in disease activity, often result in trips to the Emergency Room, the ability to predict flares with a simple blood test has important health care and health economics implications.  Paired with our pipeline of tools to analyze very large and complex clinical datasets (“Big Data”)  AMPEL’s machine learning approach is a significant step towards implementing a routine blood test for monitoring disease activity and providing decision support for drugs prescribed based on a patient’s genes. 

Therapy

After a medical team has a better understanding of a patient’s inflammatory response, it’s time for therapeutic interventions. AMPEL’s LuGENE®️ approach identifies existing FDA-approved drugs that could be repositioned, or repurposed, to interfere with the autoimmune or inflammatory response. 

Therapy

After a medical team has a better understanding of a patient’s inflammatory response, it’s time for therapeutic interventions. AMPEL’s CovGENETM approach identifies existing FDA-approved drugs that could be repositioned, or repurposed, to interfere with cytokine storms, macrophage activation, and other mechanisms that lead to severe lung damage.

A Major Step Forward in Lupus Management

Patients with autoimmune diseases like Lupus often do not know what triggers a flare or when one may occur. LuGENE®️ will transform the way doctors manage chronic diseases by using the information gathered by the lab test and analyzed by machine learning to predict a flare and treat it before it even begins, saving patients from pain and inconvenience of a disease that otherwise drastically affects their lives. 

About AMPEL BioSolutions

Precise Personalized Medicine through Genomics:
Harnessing Big Data to Improve Healthcare

IMG_0423
IMG_2172

AMPEL BioSolutions was founded to bring personalized precision medicine to patients with diseases involving the immune system and inflammation.  In 2022, AMPEL expects to commercialize it’s first product, a CLIA-certified blood test for patients/physicians called LuGENE® that assesses disease state/flares and best drug option(s).  AMPEL’s technology covers >95% of all known genes and is disease agnostic so there is capacity to expand reporting of results into new disease indications without developing a new test.  AMPEL’s exclusive curated database of >10,000 Lupus patient gene expression profiles with rich clinical information is the world’s largest and fuels machine learning predictions based on evidence.  AMPEL’s current customers are Pharma/Biotech for design/management Lupus clinical trials and patient stratification using its proprietary genomic platform, bioinformatic tools and ML/AI algorithms.  

AMPEL’s co-founders, Amrie Grammer and Peter Lipsky, are internationally recognized scientists and successful entrepreneurs, having founded and managed AMPEL to profitability consistently for 5+ years.  Their success has been a combination of world-class science with business acumen.  Dr. Grammer was elected to the class of 2021 of SIBF (Society of International Business Fellows), an organization of 1400 in 45 countries world-wide and was awarded a Virginia SBIG grant from AMPEL’s first investment round.  She is a second term board member of Virginia Bio.

Before co-founding AMPEL in 2013, Dr. Lipsky was the Director of the Intramural Research Program and the Autoimmunity Branch of NIAMS at the NIH.  Peter’s career has been distinguished by multiple scientific awards including the Carol Nachman Prize, the American College of Rheumatology Distinguished Investigator Award and the Arthritis Foundation’s prestigious Lee Howley prize.  Dr. Grammer has over 20+ years experience in genomics and managed a highly productive NIH laboratory before co-founding AMPEL.  Dr. Grammer received multiple awards for her team’s work comparing genes expressed in patients compared with healthy individuals, including the prestigious Director’s Award and mentoring awards from the American Association of Immunologists.  AMPEL’s work has been featured at the Precision Medicine World Conference and at the Biotech Showcase of JP Morgan.

News & Events

AmrieTomTom

LuGENE®️ Blood Test Expected to Launch in 2022

Machine Learning Approaches to Predict Lupus Disease Activity from Gene Expression Data The integration of gene expression data to predict systemic lupus erythematosus (SLE) disease activity is a significant challenge because of the high degree of heterogeneity among patients and

Read More »

Strategic Opportunities

Contract with AMPEL for patient stratification and pre-clinical model work.  AMPEL uses it’s genomic platform, bioinformatic tools and machine learning algorithms to assist with real-time patient screening during clinical trial enrollment and pipeline assessment for any disease.

For more information on the LuGENE®️ Manage blood test                     or strategic opportunities, please fill out the form below.

You can also call (434) 296-AMPL (2675) or email us at info@ampel.org.